Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Novel MS Drug Offers Good Functional Outcomes
Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD.
Integrated genomic and prospective clinical studies show the importance of modular pleiotropy for disease susceptibility, diagnosis and treatment.
Paraoxonase 1 activity in multiple sclerosis patients during mitoxantrone therapy.
Development of cladribine at Scripps for hairy cell leukemia and current results.
Altered serum content of brain-derived neurotrophic factor isoforms in multiple sclerosis.
Evaluation of pattern-reversal visual evoked potential in patients with neuromyelitis optica.
Immunomodulatory therapeutic effect of glatiramer acetate on several murine models of inflammatory bowel disease.
The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients.
Enhancement of axonal potassium conductance reduces nerve hyperexcitability in an in vitro model of oxaliplatin-induced acute neuropathy.
Neuromyelitis optica: Evaluation of 871 attacks and 1153 treatment courses.
Patient Satisfaction with the New Interferon Beta-1b Autoinjector (BETACONNECT™).
Biogen Idec submits application to FDA for approval of PLEGRIDY™ (peginterferon beta-1a) in multiple sclerosis
Gastrointestinal Tolerability of Delayed-Release Dimethyl Fumarate in a Multicenter, Open-Label Study of Patients with Relapsing Forms of Multiple Sclerosis (MANAGE).
Raxone®/Catena® (idebenone)
Current and future disease-modifying therapies in multiple sclerosis.
Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis.
Immunosuppressive properties of mesenchymal stem cells: advances and applications.
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.
Daclizumab discontinue letter for the US market
Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration.
Zebrafish myelination: a transparent model for remyelination?
Development of interferon beta-neutralising antibodies in multiple sclerosis-a systematic review and meta-analysis.
Tcelna® (imilecleucel-T)
No Differences Observed among Multiple Clinical S1P1 Receptor Agonists (Functional Antagonists) in S1P1 Receptor Down-regulation and Degradation.

Pages